Durvalumab (Imfinzi®) is a PD-L1 inhibitor belonging to the IgG1 subclass, approved by the FDA in 2017 for the treatment of urothelial carcinoma and NSCLC (13, 82), while inducing hypothyroidism and hyperthyroidism as irAEs (64). The gene discussed is CD274; the disease is hypothyroidism.